SEP 9, 2026 · PHASE 2/3 TRIAL
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
ClinicalTrials.gov
A terminated Phase 2/3 RCT with no results posted; the registry record documents planned design and enrollment only, without outcome data or efficacy findings.
Reported
Planned enrollment216
PhasePhase 2, Phase 3
Primary outcome measureAlzheimer's Disease Assessment Scale Cognit…